• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脊髓性肌萎缩症:从组织特异性到治疗策略

Spinal muscular atrophy: from tissue specificity to therapeutic strategies.

作者信息

Iascone Daniel M, Henderson Christopher E, Lee Justin C

机构信息

Department of Rehabilitation and Regenerative Medicine, Center for Motor Neuron Biology and Disease, Columbia University Medical Center 630 West 168th Street, New York, NY 10032 USA ; Department of Neuroscience, Columbia Translational Neuroscience Initiative, Columbia University Medical Center 630 West 168th Street, New York, NY 10032 USA.

出版信息

F1000Prime Rep. 2015 Jan 5;7:04. doi: 10.12703/P7-04. eCollection 2015.

DOI:10.12703/P7-04
PMID:25705387
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4311279/
Abstract

Spinal muscular atrophy (SMA) is the most frequent genetic cause of death in infants and toddlers. All cases of spinal muscular atrophy result from reductions in levels of the survival motor neuron (SMN) protein, and so SMN upregulation is a focus of many preclinical and clinical studies. We examine four issues that may be important in planning for therapeutic success. First, neuromuscular phenotypes in the SMNΔ7 mouse model closely match those in human patients but peripheral disease manifestations differ, suggesting that endpoints other than mouse lifespan may be more useful in predicting clinical outcome. Second, SMN plays important roles in multiple central and peripheral cell types, not just motor neurons, and it remains unclear which of these cell types need to be targeted therapeutically. Third, should SMN-restoration therapy not be effective in all patients, blocking molecular changes downstream of SMN reduction may confer significant benefit, making it important to evaluate therapeutic targets other than SMN. Lastly, for patients whose disease progression is slowed, but who retain significant motor dysfunction, additional approaches used to enhance regeneration of the neuromuscular system may be of value.

摘要

脊髓性肌萎缩症(SMA)是婴幼儿期最常见的遗传性死亡原因。所有脊髓性肌萎缩症病例均由存活运动神经元(SMN)蛋白水平降低所致,因此SMN上调是许多临床前和临床研究的重点。我们探讨了在规划治疗成功时可能很重要的四个问题。第一,SMNΔ7小鼠模型中的神经肌肉表型与人类患者的表型密切匹配,但外周疾病表现有所不同,这表明除小鼠寿命外的其他终点可能在预测临床结果方面更有用。第二,SMN在多种中枢和外周细胞类型中发挥重要作用,而不仅仅是运动神经元,目前尚不清楚这些细胞类型中哪些需要进行治疗靶向。第三,如果SMN恢复疗法并非对所有患者都有效,阻断SMN减少下游的分子变化可能会带来显著益处,因此评估除SMN之外的治疗靶点很重要。最后,对于疾病进展减缓但仍保留明显运动功能障碍的患者,用于增强神经肌肉系统再生的其他方法可能有价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d45/4311279/3d9cfe50e6fe/biolrep-07-04-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d45/4311279/52b4f7bf1ce1/biolrep-07-04-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d45/4311279/3d9cfe50e6fe/biolrep-07-04-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d45/4311279/52b4f7bf1ce1/biolrep-07-04-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d45/4311279/3d9cfe50e6fe/biolrep-07-04-g002.jpg

相似文献

1
Spinal muscular atrophy: from tissue specificity to therapeutic strategies.脊髓性肌萎缩症:从组织特异性到治疗策略
F1000Prime Rep. 2015 Jan 5;7:04. doi: 10.12703/P7-04. eCollection 2015.
2
Chronic treatment with lithium does not improve neuromuscular phenotype in a mouse model of severe spinal muscular atrophy.慢性锂治疗不能改善严重脊髓性肌萎缩症小鼠模型的神经肌肉表型。
Neuroscience. 2013 Oct 10;250:417-33. doi: 10.1016/j.neuroscience.2013.07.026. Epub 2013 Jul 19.
3
Therapeutic strategies for spinal muscular atrophy: SMN and beyond.脊髓性肌萎缩症的治疗策略:生存运动神经元蛋白及其他
Dis Model Mech. 2017 Aug 1;10(8):943-954. doi: 10.1242/dmm.030148.
4
The neuromuscular impact of symptomatic SMN restoration in a mouse model of spinal muscular atrophy.脊髓性肌萎缩症小鼠模型中有症状性生存运动神经元恢复的神经肌肉影响
Neurobiol Dis. 2016 Mar;87:116-23. doi: 10.1016/j.nbd.2015.12.014. Epub 2015 Dec 28.
5
CHP1 reduction ameliorates spinal muscular atrophy pathology by restoring calcineurin activity and endocytosis.CHP1 减少通过恢复钙调神经磷酸酶活性和内吞作用改善脊髓性肌萎缩症病理。
Brain. 2018 Aug 1;141(8):2343-2361. doi: 10.1093/brain/awy167.
6
Therapeutics development for spinal muscular atrophy.脊髓性肌萎缩症的治疗研发
NeuroRx. 2006 Apr;3(2):235-45. doi: 10.1016/j.nurx.2006.01.010.
7
Loganin possesses neuroprotective properties, restores SMN protein and activates protein synthesis positive regulator Akt/mTOR in experimental models of spinal muscular atrophy.马钱苷具有神经保护特性,可恢复运动神经元生存蛋白(SMN)并在脊髓性肌萎缩症实验模型中激活蛋白质合成正向调节因子Akt/哺乳动物雷帕霉素靶蛋白(mTOR)。
Pharmacol Res. 2016 Sep;111:58-75. doi: 10.1016/j.phrs.2016.05.023. Epub 2016 May 27.
8
Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape.脊髓性肌萎缩症:反义寡核苷酸疗法为综合治疗格局打开了大门。
Hum Mol Genet. 2017 Oct 1;26(R2):R151-R159. doi: 10.1093/hmg/ddx215.
9
Development and characterization of an SMN2-based intermediate mouse model of Spinal Muscular Atrophy.开发并鉴定基于 SMN2 的中间型脊髓性肌萎缩症小鼠模型。
Hum Mol Genet. 2013 May 1;22(9):1843-55. doi: 10.1093/hmg/ddt037. Epub 2013 Feb 5.
10
Advances in modeling and treating spinal muscular atrophy.脊髓性肌萎缩症建模与治疗的进展
Curr Opin Neurol. 2016 Oct;29(5):549-56. doi: 10.1097/WCO.0000000000000368.

引用本文的文献

1
Motor pool selectivity of neuromuscular degeneration in type I spinal muscular atrophy is conserved between human and mouse.I型脊髓性肌萎缩症中神经肌肉变性的运动神经元池选择性在人类和小鼠之间是保守的。
Hum Mol Genet. 2025 Feb 8;34(4):347-367. doi: 10.1093/hmg/ddae190.
2
Improved gene therapy for spinal muscular atrophy in mice using codon-optimized hSMN1 transgene and hSMN1 gene-derived promotor.使用密码子优化的 hSMN1 转基因和 hSMN1 基因启动子改善小鼠的脊髓性肌萎缩症基因治疗。
EMBO Mol Med. 2024 Apr;16(4):945-965. doi: 10.1038/s44321-024-00037-x. Epub 2024 Feb 27.
3
Neuromuscular denervation and deafferentation but not motor neuron death are disease features in the Smn2B/- mouse model of SMA.

本文引用的文献

1
Olesoxime (TRO19622): A Novel Mitochondrial-Targeted Neuroprotective Compound.羟苯磺酸己酯(TRO19622):一种新型线粒体靶向神经保护化合物。
Pharmaceuticals (Basel). 2010 Jan 28;3(2):345-368. doi: 10.3390/ph3020345.
2
Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy.运动神经元疾病。SMN2 剪接修饰物可改善脊髓性肌萎缩症小鼠的运动功能和寿命。
Science. 2014 Aug 8;345(6197):688-93. doi: 10.1126/science.1250127.
3
Observational study of spinal muscular atrophy type I and implications for clinical trials.
神经肌肉去神经和去传入而不是运动神经元死亡是 SMA 的 Smn2B/- 小鼠模型的疾病特征。
PLoS One. 2022 Aug 1;17(8):e0267990. doi: 10.1371/journal.pone.0267990. eCollection 2022.
4
Central synaptopathy is the most conserved feature of motor circuit pathology across spinal muscular atrophy mouse models.中枢突触病变是脊髓性肌萎缩症小鼠模型运动回路病理学中最保守的特征。
iScience. 2021 Oct 30;24(11):103376. doi: 10.1016/j.isci.2021.103376. eCollection 2021 Nov 19.
5
Dual SMN inducing therapies can rescue survival and motor unit function in symptomatic ∆7SMA mice.双重 SMN 诱导疗法可挽救症状性 ∆7SMA 小鼠的生存和运动单位功能。
Neurobiol Dis. 2021 Nov;159:105488. doi: 10.1016/j.nbd.2021.105488. Epub 2021 Aug 20.
6
Spinal Muscular Atrophy: Huge Steps.脊髓性肌萎缩症:巨大进展。
Cerebrum. 2019 Mar 1;2019. eCollection 2019 Mar-Apr.
7
Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts.脊髓性肌萎缩症患者成纤维细胞中剪接转换反义寡核苷酸诱导的外显子包含情况评估
J Vis Exp. 2018 May 11(135):57530. doi: 10.3791/57530.
8
Blocking p62-dependent SMN degradation ameliorates spinal muscular atrophy disease phenotypes.阻断 p62 依赖性 SMN 降解可改善脊髓性肌萎缩症的疾病表型。
J Clin Invest. 2018 Jul 2;128(7):3008-3023. doi: 10.1172/JCI95231. Epub 2018 Jun 11.
9
An open source tool for automatic spatiotemporal assessment of calcium transients and local 'signal-close-to-noise' activity in calcium imaging data.一个用于自动时空评估钙瞬变和钙成像数据中局部“信号接近噪声”活动的开源工具。
PLoS Comput Biol. 2018 Mar 30;14(3):e1006054. doi: 10.1371/journal.pcbi.1006054. eCollection 2018 Mar.
10
LNA/DNA mixmer-based antisense oligonucleotides correct alternative splicing of the SMN2 gene and restore SMN protein expression in type 1 SMA fibroblasts.基于 LNA/DNA 嵌合体的反义寡核苷酸纠正 1 型 SMA 成纤维细胞中 SMN2 基因的可变剪接,并恢复 SMN 蛋白表达。
Sci Rep. 2017 Jun 16;7(1):3672. doi: 10.1038/s41598-017-03850-2.
I型脊髓性肌萎缩症的观察性研究及其对临床试验的意义。
Neurology. 2014 Aug 26;83(9):810-7. doi: 10.1212/WNL.0000000000000741. Epub 2014 Jul 30.
4
Spinal muscular atrophy: journeying from bench to bedside.脊髓性肌萎缩症:从实验室到临床的历程
Neurotherapeutics. 2014 Oct;11(4):786-95. doi: 10.1007/s13311-014-0293-y.
5
Systemic administration of a recombinant AAV1 vector encoding IGF-1 improves disease manifestations in SMA mice.系统性给予编码胰岛素样生长因子-1(IGF-1)的重组腺相关病毒1型(AAV1)载体可改善脊髓性肌萎缩症(SMA)小鼠的疾病表现。
Mol Ther. 2014 Aug;22(8):1450-1459. doi: 10.1038/mt.2014.84. Epub 2014 May 12.
6
Mechanisms involved in spinal cord central synapse loss in a mouse model of spinal muscular atrophy.脊髓性肌萎缩症小鼠模型中脊髓中枢突触丧失的相关机制。
J Neuropathol Exp Neurol. 2014 Jun;73(6):519-35. doi: 10.1097/NEN.0000000000000074.
7
SMN control of RNP assembly: from post-transcriptional gene regulation to motor neuron disease.运动神经元存活蛋白对核糖核蛋白组装的调控:从转录后基因调控到运动神经元疾病
Semin Cell Dev Biol. 2014 Aug;32:22-9. doi: 10.1016/j.semcdb.2014.04.026. Epub 2014 Apr 24.
8
Survival motor neuron protein deficiency impairs myotube formation by altering myogenic gene expression and focal adhesion dynamics.生存运动神经元蛋白缺乏通过改变生肌基因表达和粘着斑动力学来损害肌管形成。
Hum Mol Genet. 2014 Sep 15;23(18):4745-57. doi: 10.1093/hmg/ddu189. Epub 2014 Apr 23.
9
Myogenic program dysregulation is contributory to disease pathogenesis in spinal muscular atrophy.成肌程序失调促成脊髓性肌萎缩症的疾病发病机制。
Hum Mol Genet. 2014 Aug 15;23(16):4249-59. doi: 10.1093/hmg/ddu142. Epub 2014 Apr 1.
10
Dysregulation of ubiquitin homeostasis and β-catenin signaling promote spinal muscular atrophy.泛素稳态失调和β-连环蛋白信号通路的失调促进了脊髓性肌萎缩症的发生。
J Clin Invest. 2014 Apr;124(4):1821-34. doi: 10.1172/JCI71318. Epub 2014 Mar 3.